ETEshetu Tefera

Eshetu Tefera

*This is an algorithmically generated author record based on publicly available information.

Eshetu Tefera has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and tolerability of oral morphine versus oxycodone/acetaminophen for analgesia in the emergency department

    by Hayley Harvey, Maria Cacciapuoti, Leena Ramadan, Katherine Brodie, Colin Gibson, Eshetu Tefera, MD Gregory G. Yu, Sergey M. Motov, Lewis S. Nelson, Maryann Mazer-Amirshahi

    Objective: Oxycodone/acetaminophen is one of the most commonly prescribed medications for pain management in the emergency department (ED) despite its high abuse liability. Our objective was to determine whether oral immediate-release morphine is as effective and well tolerated as oral oxycodone/acetaminophen for pain relief in stable ED patients. Design: This is a prospective comparative study in which stable adult patients with acute painful conditions who had either oral morphine (15 or 30 mg) or oxycodone/ acetaminophen (5/325 mg or 10/650 mg) ordered for them at the discretion of a triage physician were recruited. Setting: This study took place in an urban, academic ED from 2016 to 2019. Participants: Seventy-three percent of the subjects were between the ages of 18 and 59, 57 percent were female, and 85 percent were African American. Most presented with abdominal, extremity, or back pain. Patient characteristics were similar between treatment groups. Interventions: Of the 364 enrolled patients, 182 were given oral morphine and 182 were given oxycodone/acetaminophen at the discretion of the triage provider. They were asked to rate their pain score prior to receiving analgesia and at 60 and 90 minutes after administration. Main outcome measures: We examined pain scores, adverse effects, overall satisfaction, willingness to accept the same treatment again, and the need for additional analgesia. Results: There was no difference in satisfaction reported by patients who received morphine versus oxycodone/acetaminophen: 15.9 percent vs 16.5 percent were very satisfied, 31.9 percent vs 26.4 percent were somewhat satisfied, and 23.6 percent vs 22.5 percent were not satisfied, p = 0.56. Secondary outcomes also showed no significant difference: net change in pain score –2 vs –2 at 60 and 90 minutes, p = 0.91 and p = 0.72, respectively; adverse effects 20.9 percent vs 19.2 percent, p = 0.69; need for further analgesia 9.3 percent vs 7.1 percent, p = 0.44; willingness to accept analgesic again 73.1 percent vs 78.6 percent, p = 0.22. Conclusions: Oral morphine is a feasible alternative to oxycodone/acetaminophen for analgesia in the ED.


  • Open Access

    Response to Letter to the Editor from Zandee and Links: “Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for 131I Administration”

    by Cristiane J Gomes-Lima, Sanjita Chittimoju, Leen Wehbeh, Sunita Dia, Prathyusha Pagadala, Mohammad Al-Jundi, Sakshi Jhawar, Eshetu Tefera, Mihriye Mete, Joanna Klubo-Gwiezdzinska, et al.

    Cristiane J Gomes-Lima, Sanjita Chittimoju, Leen Wehbeh, Sunita Dia, Prathyusha Pagadala, Mohammad Al-Jundi, Sakshi Jhawar, Eshetu Tefera, Mihriye Mete, Joanna

  • Open Access

    Bacitracin for Injection Recall: Impact on Immediate Breast Implant Surgical Outcomes

    by Abigail R. Tirrell, Jenna C. Bekeny, Eshetu A. Tefera, David H. Song, Kenneth L. Fan

    Background. Triple-antibiotic irrigation of breast implant pockets is a mainstay of infection prophylaxis in breast reconstruction and augmentation. The recall of bacitracin for injection due to risk of anaphylaxis and nephrotoxicity in January 2020, a staple component of the irrigation solution, has raised concern for worsened postoperative sequelae. This study aimed to investigate pre- and post-recall implant-based breast surgery to analyze the impact of bacitracin in irrigation solutions on infection rates. Methods. All implant-based breast reconstruction or augmentation surgeries from January 2019 to February 2021 were retrospectively reviewed. In a regression discontinuity study design, patients were divided into pre- and post-recall groups. Patient demographics, surgical details, and outcomes including infection rates were collected. Differences in complication rates were compared between groups and with surgical and patient factors. Results. 254 implants in 143 patients met inclusion criteria for this study, with 172 implants placed before recall and 82 placed after recall. Patients in each cohort did not differ in age, BMI, smoking status, or history of breast radiation or capsular contracture ( ). All breast pockets were irrigated with antibiotic solution, most commonly bacitracin, cefazolin, gentamycin, and povidone-iodine before recall (116,67.4%) and cefazolin, gentamycin, and povidone-iodine after recall (59,72.0%). There was no difference in incidence of infection (6.4% vs. 8.5%, ) or cellulitis (3.5% vs. 3.7%, ) before and after recall. Implant infection was associated with smoking history ( ) and increased surgical time ( ). Conclusions. Despite the recent recall of bacitracin from inclusion in breast pocket irrigation solutions, our study demonstrated no detrimental impact on immediate complication rates. This shift in irrigation protocols calls for additional investigations into optimizing antibiotic combinations in solution, as bacitracin is no longer a viable option, to improve surgical outcomes and long-term benefits.


  • Open Access

    Outcomes in drainage ankle disarticulation vs. guillotine transtibial amputation in the staged approach to below knee amputation

    by Alissa M. Mayer, Nicole K. Cates, Eshetu Tefera, Kevin K. Ragothaman, Kenneth Fan, Karen K. Evans, John S. Steinberg, Christopher E. Attinger

  • Open Access

    Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for 131I Administration

    by Cristiane J Gomes-Lima, Sanjita Chittimoju, Leen Wehbeh, Sunita Dia, Prathyusha Pagadala, Mohammad Al-Jundi, Sakshi Jhawar, Eshetu Tefera, Mihriye Mete, Joanna Klubo-Gwiezdzinska, et al.

    Context Recombinant human thyrotropin (rhTSH) is currently not Food and Drug Administration approved for the treatment of high-risk patients with differentiated thyroid cancer (DTC). Objective The goal of our study was to compare the outcomes in higher-risk patients with metastatic DTC prepared for radioiodine (RAI) therapy with rhTSH vs thyroid hormone withdrawal (THW). Methods A retrospective chart review was performed of patients with metastatic DTC in follow-up at MedStar Washington Hospital Center and MedStar Georgetown University Hospital from 2009 to 2017. Patients were divided according to their preparation for RAI therapy, with assessment of progression-free survival (PFS) and overall survival (OS). Results Fifty-five patients with distant metastases (16 men, 39 women) were prepared for RAI therapy exclusively either with rhTSH (n = 27) or with THW (n = 28). There were no statistically significant differences between the groups regarding clinicopathological features and history of RAI therapies. The median follow-up time for patients with rhTSH-aided therapies was 4.2 years (range, 3.3-5.5 years) and for patients with THW-aided therapies was 6.8 years (range, 4.2-11.6 years) (P = .002). Multivariate analysis showed that the method of thyrotropin stimulation was not associated with a difference in PFS or OS. Conclusion As has been shown previously for low-risk DTC, this study indicates that the mode of preparation for RAI therapy does not appear to influence the outcomes of patients with metastatic DTC. PFS and OS were similar for patients with THW-aided or rhTSH-aided RAI therapies.


  • Double Versus Triple Arthrodesis Fusion Rates: A Systematic Review

    by Nicole K. Cates, Alissa Mayer, Jonathan Tenley, Jacob Wynes, Eshetu Tefera, John S. Steinberg, Paul J. Kim, Glenn M. Weinraub


  • Risks Factors Associated With Major Lower Extremity Amputation After Vertical Contour Calcanectomy

    by Helene R. Cook, Nicole K. Cates, Christopher J. Kennedy, Eshetu Tefera, Daniel Popovsky, Kevin Delijani, Paul J. Kim, Christopher E. Attinger, John S. Steinberg


  • Risk Factors for Loss to Follow-Up in the Lower Extremity Limb Salvage Population

    by Banafsheh Sharif-Askary, Elizabeth G. B.S. Zolper, Romina Deldar, Eshetu M.S. Tefera, Abigail R. B.S. Tirrell, Areeg A. B.S. Abu El Hawa, Christopher E. Attinger, Karen K. Evans, Kenneth L. Fan

    Background: Limb salvage for chronic lower extremity wounds requires long-term care best delivered by specialized multidisciplinary centers. This optimizes function, reduces amputation rates, and improves mortality. These centers may be limited to urban/academic settings, making access and appropriate follow-up challenging. Therefore, the authors hypothesize that both system- and patient-related factors put this population at exceedingly high risk for loss to follow-up. Methods: Records were reviewed retrospectively for 200 new patients seen at the Georgetown Center for Wound Healing in 2013. The primary outcome was loss to follow-up, defined as three consecutive missed appointments despite explicit documentation indicating the need for return visits. Demographic, clinical, and geographic data were compared. Multivariate logistic regression analysis for loss to follow-up status controlled for variables found significant in the bivariate analysis. Spatial dependency was evaluated using variograms. Results: Over a 6.5-year-period, 49.5 percent of patients followed were lost to follow-up. Male sex and increased driving distance to the limb salvage center were risk factors for loss to follow-up. Wound-specific characteristics including ankle and knee/thigh location were also associated with higher rates of loss to follow-up. There was no spatial dependency or discrete clustering of at-risk patients. Conclusions: This study is the first of its kind to investigate the demographic and clinical characteristics that predispose chronic lower extremity wound patients to loss to follow-up. These findings inform stakeholders of the high rates of loss to follow-up and support decentralized specialty care, in the form of telemedicine, satellite facilities, and/or dedicated case managers. Future work will focus on targeting vulnerable populations through focused interventions to reduce patient and system burden. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.


  • P09.25 Role of Immune Checkpoint Inhibitors (ICPi) in KRAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

    by M. Peravali, C. Gomes-Lima, E. Tefera, M. Baker, M. Sherchan, S. Farid, K. Burman, F. Constantinescu, I. Veytsman